Publication | Open Access

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

Pretreated PatientsNovel TherapyMedicinePharmacologyClinical TrialsEgfr-mutated Advanced NsclcPharmacotherapyCancer TreatmentOncologyPhase 1Lung Cancer